Catherine Magazu

Catherine Magazu is a Partner in the firm’s Life Sciences group. She joined Goodwin in 2014.

Catherine represents public and private companies in the pharmaceutical, biotechnology, and medical device industries. She advises clients in a variety of corporate matters, including start-up and formation matters, venture capital financings, initial public offerings, and capital markets transactions, strategic investments, and other general corporate matters.

While attending law school, Catherine was a member of the American Journal for Law & Medicine and received the Dean’s Award in Professional Responsibility.

• Sionna Therapeutics in its $182 million Series C financing
• Royalty Pharma in its agreement with PTC Therapeutics to acquire additional royalties on Roche’s Evrysdi for $1 billion upfront
• Orchard Therapeutics in its $387 million acquisition by Kyowa Kirin, $225.5 million initial public offering and initial U.S. listing, $128.3 million follow-on offering and its $150 million PIPE
• Royalty Pharma in its acquisition of an interest in Ionis Pharmaceuticals’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.12 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments
• Royalty Pharma in its agreement with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia
• eGenesis in its $100 million Series B financing, $125 million Series C financing, and its acquisition of the assets and operations of ICBiotec 
• Yumanity Therapeutics in more than $100 million in private equity financings, as well as debt financings, its merger with Proteostasis Therapeutics and concurrent PIPE, and its merger with Kineta
• Delix Therapeutics on its $70 Million Series A financing 
• AVROBIO in its seed financing with Atlas Ventures, $25 million and $60 million private financings, $115 million initial public offering and more than $200 million in follow-on public offerings
• Regenacy Pharmaceuticals in its Series A and Series B financings
• Zealand Pharma in the $205 million royalty and milestone monetization from Royalty Pharma of Zealand’s GLP-1 diabetes franchise
• Barings in the purchase of certain rights from George Washington University related to the license by GWU of its vasoconstrictor drug to La Jolla Pharmaceutical Company
• Onxeo in the $7.5 million royalty and milestone monetization from SWK Holdings of Onxeo’s oncology drug to treat refractory peripheral T cell lymphoma
• Rodin Therapeutics in its private equity financings and $950 million sale to Alkermes 
• Surface Oncology in its $108 million initial public offering and concurrent $11.5 million private placement
• Acetylon Pharmaceuticals in its sale to Celgene Corporation and its spin-out of Regency Pharmaceuticals 
• Dimension Therapeutics in its $72 million initial public offering
• Allena Pharmaceuticals in its $53 million Series C financing 
• Celyad S.A. in its $100.1 U.S. initial public offering